Shareprice catalysts 1. Achieving further in vivo efficacy for...

Shareprice catalysts
1. Achieving further in vivo efficacy for one of PYC’s FPPs: The most advanced
prospect to achieve this end is PYC’s in house iMyc program. Mice data from
the iMyc program is due in late 2017/early2018. A positive result will not only
de-risk the iMyc program but will have significant positive implications for
the entire PYC platform.
2. Partnership deals with credible third parties: Announcements in this vein
will add cash to the balance sheet, provide further third party validation and
also broaden the potential application of PYC’s FPPs.
Valuation​

We value PYC at $0.074/sh with a Spec BUY rating.

Note these two points are not dependent on each other, so we could get one or the other. But what if we get some traction on both...... ? No doubt we will have some sp appreciation leading into the announcement of the mice data. If it is good, the sp will kick. Watch out if it is not though...